Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes
Vikas S. Sridhar(University Health Network), David Z.I. Cherney(University Health Network), Hiddo J.L. Heerspink(University Medical Center Groningen), Christine P. Limonte(University of Washington Medical Center), Peter Rossing(Steno Diabetes Centers), Jay S. Skyler(University of Miami), Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Per‐Henrik Groop(University of Helsinki)
Cited by 25
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
|New England Journal of Medicine|2024|1.5k